Short Interest in Caribou Biosciences, Inc. (NASDAQ:CRBU) Increases By 7.2%

Caribou Biosciences, Inc. (NASDAQ:CRBUGet Free Report) saw a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 10,070,000 shares, a growth of 7.2% from the February 29th total of 9,390,000 shares. Based on an average trading volume of 1,650,000 shares, the days-to-cover ratio is currently 6.1 days. Approximately 12.7% of the company’s shares are sold short.

Hedge Funds Weigh In On Caribou Biosciences

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in Caribou Biosciences by 3.7% in the fourth quarter. Vanguard Group Inc. now owns 3,962,044 shares of the company’s stock worth $22,703,000 after purchasing an additional 139,893 shares during the period. Wellington Management Group LLP increased its stake in Caribou Biosciences by 57.7% in the 4th quarter. Wellington Management Group LLP now owns 314,080 shares of the company’s stock worth $1,800,000 after buying an additional 114,975 shares during the period. American International Group Inc. lifted its holdings in Caribou Biosciences by 9.2% during the 4th quarter. American International Group Inc. now owns 40,693 shares of the company’s stock valued at $233,000 after buying an additional 3,413 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Caribou Biosciences by 28.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 20,835 shares of the company’s stock valued at $120,000 after buying an additional 4,637 shares during the period. Finally, Barclays PLC grew its stake in Caribou Biosciences by 3.6% in the 4th quarter. Barclays PLC now owns 263,471 shares of the company’s stock worth $1,510,000 after acquiring an additional 9,240 shares in the last quarter. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright raised their price objective on Caribou Biosciences from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Tuesday, March 19th.

Read Our Latest Research Report on Caribou Biosciences

Caribou Biosciences Price Performance

Caribou Biosciences stock opened at $5.05 on Tuesday. The firm has a market capitalization of $456.12 million, a P/E ratio of -3.48 and a beta of 2.48. Caribou Biosciences has a 1-year low of $3.44 and a 1-year high of $8.59. The company’s 50-day moving average is $6.36 and its 200 day moving average is $5.52.

About Caribou Biosciences

(Get Free Report)

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma.

Read More

Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.